Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Keywords

GefitinibDocetaxelMedicineLung cancerInternal medicineRegimenHazard ratioPopulationOncologyChemotherapyPerformance statusCancerEpidermal growth factor receptorConfidence interval

Affiliated Institutions

Related Publications

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

Pui San Tan , Gilberto Lopes , Sanchalika Acharyya +2 more

Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefi...

2015 European Journal of Cancer 17 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Trastuzumab-Induced Hepatotoxicity: A Case Report

D. Vucicevic , Elizabeth J. Carey , Nina J. Karlin

<b><i>Background: </i></b>Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overe...

2013 Breast Care 4416 citations

Publication Info

Year: 2008
Type: article
Volume: 372
Issue: 9652
Pages: 1809-1818
Citations: 1240
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1240

OpenAlex

Cite This

APA Style

                            
                                
                                    Edward S. Kim, 
                                
                                    Vera Hirsh, 
                                
                                    Tony Mok
                                
                                et al.
                            
                            (2008). 
                            Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. 
                            The Lancet
                            , 372
                            (9652)
                            , 1809-1818.
                            https://doi.org/10.1016/s0140-6736(08)61758-4
                        

Identifiers

DOI: 10.1016/s0140-6736(08)61758-4